Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer

Guidelines Development Group European Commission Initiative on Breast Cancer

doi:https://doi.org/10.1016/S0959-8049(20)30555-4

Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer

Guidelines Development Group European Commission Initiative on Breast Cancer

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	S12-S13
Journal	European Journal of Cancer
Volume	138
DOIs	https://doi.org/10.1016/S0959-8049(20)30555-4
Publication status	Published - 1 Oct 2020

Access to Document

https://doi.org/10.1016/S0959-8049(20)30555-4

Cite this

Guidelines Development Group European Commission Initiative on Breast Cancer (2020). Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer. European Journal of Cancer, 138, S12-S13. https://doi.org/10.1016/S0959-8049(20)30555-4

Guidelines Development Group European Commission Initiative on Breast Cancer. / Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer. In: European Journal of Cancer. 2020 ; Vol. 138. pp. S12-S13.

@article{5f352ea7d58946dc9815ee5da31d999e,

title = "Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer",

author = "Rossi, {P. Giorgi} and A. Lebeau and C. Canelo-Aybar and Rivera, {M. C. Posso} and Comas, {D. Rigau} and C. Quinn and Coello, {P. Alonso} and H. McGarrigle and S. Warman and M. Broeders and S. Duffy and Langendam, {M. W.} and A. Gr{\"a}wingholt and M. Follmann and Z. Saz-Parkinson and {Guidelines Development Group European Commission Initiative on Breast Cancer} and H. Sch{\"u}nemann",

year = "2020",

month = oct,

day = "1",

doi = "https://doi.org/10.1016/S0959-8049(20)30555-4",

language = "English",

volume = "138",

pages = "S12--S13",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

Guidelines Development Group European Commission Initiative on Breast Cancer 2020, 'Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer', European Journal of Cancer, vol. 138, pp. S12-S13. https://doi.org/10.1016/S0959-8049(20)30555-4

Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer. / Guidelines Development Group European Commission Initiative on Breast Cancer.
In: European Journal of Cancer, Vol. 138, 01.10.2020, p. S12-S13.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer

AU - Rossi, P. Giorgi

AU - Lebeau, A.

AU - Canelo-Aybar, C.

AU - Rivera, M. C. Posso

AU - Comas, D. Rigau

AU - Quinn, C.

AU - Coello, P. Alonso

AU - McGarrigle, H.

AU - Warman, S.

AU - Broeders, M.

AU - Duffy, S.

AU - Langendam, M. W.

AU - Gräwingholt, A.

AU - Follmann, M.

AU - Saz-Parkinson, Z.

AU - Guidelines Development Group European Commission Initiative on Breast Cancer

AU - Schünemann, H.

PY - 2020/10/1

Y1 - 2020/10/1

UR - http://www.scopus.com/inward/record.url?scp=85091964675&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S0959-8049(20)30555-4

DO - https://doi.org/10.1016/S0959-8049(20)30555-4

M3 - Article

SN - 0959-8049

VL - 138

SP - S12-S13

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Guidelines Development Group European Commission Initiative on Breast Cancer. Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer. European Journal of Cancer. 2020 Oct 1;138:S12-S13. doi: https://doi.org/10.1016/S0959-8049(20)30555-4

Recommendations from the European Commission Initiative on Breast Cancer on multigene tests to guide the use of adjuvant chemotherapy in patients who have hormone receptor positive, HER-2 negative, lymph node negative or up to 3 lymph nodes positive invasive breast cancer

Access to Document

Other files and links

Cite this